CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden
Journal for ImmunoTherapy of Cancer · 2023-02 · 11 (2) · e005887
DOI: 10.1136/jitc-2022-005887 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 15.02.2023. Verfasst von Jitske van den Bulk und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Colorectal Neoplasms. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Leids Universitair Medisch Centrum, European Research Council.
Abstract (Originalsprache)
Background
Expression of CD103 and CD39 has been found to pinpoint tumor-reactive CD8 + T cells in a variety of solid cancers. We aimed to investigate whether these markers specifically identify neoantigen-specific T cells in colorectal cancers (CRCs) with low mutation burden. Experimental design Whole-exome and RNA sequencing of 11 mismatch repair-proficient (MMR-proficient) CRCs and corresponding healthy tissues were performed to determine the presence of putative neoantigens. In parallel, tumor-infiltrating lymphocytes (TILs) were cultured from the tumor fragments and, in parallel, CD8 + T cells were flow-sorted from their respective tumor digests based on single or combined expression of CD103 and CD39. Each subset was expanded and subsequently interrogated for neoantigen-directed reactivity with synthetic peptides. Neoantigen-directed reactivity was determined by flow cytometric analyses of T cell activation markers and ELISA-based detection of IFN-γ and granzyme B release. Additionally, imaging mass cytometry was applied to investigate the localization of CD103 + CD39 + cytotoxic T cells in tumors.
Results
Neoantigen-directed reactivity was only encountered in bulk TIL populations and CD103 + CD39 + (double positive, DP) CD8 + T cell subsets but never in double-negative or single-positive subsets. Neoantigen-reactivity detected in bulk TIL but not in DP CD8 + T cells could be attributed to CD4 + T cells. CD8 + T cells that were located in direct contact with cancer cells in tumor tissues were enriched for CD103 and CD39 expression.
Conclusion
Coexpression of CD103 and CD39 is characteristic of neoantigen-specific CD8 + T cells in MMR-proficient CRCs with low mutation burden. The exploitation of these subsets in the context of adoptive T cell transfer or engineered T cell receptor therapies is a promising avenue to extend the benefits of immunotherapy to an increasing number of CRC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands.
- Basic Immunology Lab, Earle A Chiles Research Institute, Portland, Oregon, USA.
- Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, The Netherlands.
- Anti-Cancer Immune Response Lab, Earle A Chiles Research Institute, Portland, Oregon, USA.
- Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands N.F.de_Miranda@lumc.nl.
ORCID-Profile: Jitske van den Bulk, Els M E Verdegaal, Thomas Duhen, Noel F C C de Miranda
Förderung
- Leids Universitair Medisch Centrum
- European Research Council
Zitieren
APA
van den Bulk, J., van der Ploeg, M., Ijsselsteijn, M. E., Ruano, D., van der Breggen, R., Duhen, R., Peeters, K. C. M. J., Fariña-Sarasqueta, A., Verdegaal, E. M. E., van der Burg, S. H., Duhen, T., & de Miranda, N. F. C. C. (2023). CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden. Journal for ImmunoTherapy of Cancer, 11(2), e005887. https://doi.org/10.1136/jitc-2022-005887
Vancouver
van den Bulk J, van der Ploeg M, Ijsselsteijn ME, Ruano D, van der Breggen R, Duhen R, et al. CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden. Journal for ImmunoTherapy of Cancer. 2023;11(2):e005887. doi:10.1136/jitc-2022-005887
BibTeX
@article{vandenBulk2023,
author = {van den Bulk, Jitske and van der Ploeg, Manon and Ijsselsteijn, Marieke E and Ruano, Dina and van der Breggen, Ruud and Duhen, Rebekka and Peeters, Koen C M J and Fariña-Sarasqueta, Arantza and Verdegaal, Els M E and van der Burg, Sjoerd H and Duhen, Thomas and de Miranda, Noel F C C},
title = {CD103 and CD39 coexpression identifies neoantigen-specific cytotoxic T cells in colorectal cancers with low mutation burden},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2023},
volume = {11},
number = {2},
pages = {e005887},
doi = {10.1136/jitc-2022-005887}
}
EUVIMED